...
首页> 外文期刊>The international journal of biochemistry and cell biology >MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-beta/Smad pathway in hepatocellular carcinoma
【24h】

MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-beta/Smad pathway in hepatocellular carcinoma

机译:MicroRNA-181A-5P通过靶向EGR1和抑制肝细胞癌中的EGR1 / TGF-β/ Smad途径来抑制细胞增殖

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Hepatocellular carcinoma (HCC) is the leading cause of cancer mortality worldwide. Early growth response factor 1 (Egr1) plays a crucial role in cancer progression. However, its precise role in HCC has not been clear. Here, we identified the aggravating role of Egr1 in cell proliferation of HCC firstly. The expression of Egr1 was significantly increased in HCC tissues. Functionally, overexpression of Egr1 enhanced, whereas silenced Egr1 expression attenuated HCC cells proliferation in vitro. Mechanistically, up-regulated Egr1 induced cell proliferation through activating Transforming growth factor (TGF)-beta 1/Smad signaling pathway concomitantly with upregulation of p-Smad2 and p-Smad3. Secondly, miR-181a-5p was down-regulated in clinical HCC specimens and its expression was inversely correlated with Egr1 expression. Functionally, overexpression of miR-181a-5p inhibited, whereas decreased expression of miR-181a-5p promoted HCC cells proliferation in vitro. Furthermore, we demonstrated that miR-181a-5p overexpression directly suppressed Egr1, resulting in a down-regulated TGF-beta 1/Smad pathway. Besides, the silenced Egr1 expression could rescue the enhanced cell proliferation induced by miR-181a-5p inhibitor. Thus, we concluded that miR-181a-5p is a negative regulator of Egr1 that can suppress tumor proliferation in HCC through targeting Egr1/TGF-beta 1/Smad pathway, which may be a potential therapeutic approach of HCC.
机译:肝细胞癌(HCC)是全世界癌症死亡率的主要原因。早期生长响应因子1(EGR1)在癌症进展中起着至关重要的作用。但是,其在HCC中的确切作用并不清楚。在这里,我们首先确定了EGR1在HCC细胞增殖中的加剧作用。 HCC组织中EGR1的表达显着增加。在功能上,EGR1的过表达增强,而沉默的EGR1表达减弱了HCC细胞在体外增殖。机械上,上调的EGR1诱导细胞增殖,通过激活转化生长因子(TGF)-Beta 1 / Smad信号传导途径,其伴随着p-Smad2和P-Smad3的上调。其次,在临床HCC标本中下调miR-181a-5p,其表达与EGR1表达相反。在功能上,抑制miR-181a-5p的过表达,而MiR-181A-5P的表达降低促进HCC细胞的体外增殖。此外,我们证明了MiR-181A-5P过表达直接抑制EGR1,导致下调的TGF-β1/ Smad途径。此外,沉默的EGR1表达可以拯救MIR-181A-5P抑制剂诱导的增强的细胞增殖。因此,我们得出结论,miR-181a-5p是EGR1的负调节剂,其可以通过靶向EGR1 / TGF-β1/ smad途径来抑制HCC中的肿瘤增殖,这可能是HCC的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号